All > San Diego > Louisiana

Povorcitinib Dose B for Hidradenitis Suppurativa

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Investigative Site US200, Ocala, FLHidradenitis SuppurativaPovorcitinib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new drug to treat painful skin condition hidradenitis suppurativa over a 54-week period.

Eligible Conditions
  • Hidradenitis Suppurativa

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
CDX-0159
1
Ruxolitinib Cream
1
Sonelokimab (M1095)

Study Objectives

1 Primary · 18 Secondary · Reporting Duration: From Week 12 through Week 54

12 Weeks
Proportion of participants with flare
54 weeks
Mean change from baseline in Dermatology Life Quality Index (DLQI) score
Mean change from baseline in abscess count
Mean change from baseline in draining tunnel count
Bacterial Count Measurement
Percentage change from baseline in abscess count
Percentage change from baseline in draining tunnel count
Inflammation
Week 54
Extension Period: Proportion of participants who achieve maintenance of HiSCR or greater response at each visit
Extension Period: Proportion of participants who achieve maintenance of HiSCR75 or greater response at each visit
Extension Period: Proportion of participants with flare
Week 12
Hidradenitis
Hidradenitis
Pain
Pain
Fatigue
Week 54
Extension Period: Proportion of participants who achieve HiSCR
Extension Period: Proportion of participants who achieve HiSCR75
Pain

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
CDX-0159
2
Ruxolitinib Cream
2
Sonelokimab (M1095)

Trial Design

3 Treatment Groups

Povorcitinib Dose B
1 of 3
Povorcitinib Dose A
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

600 Total Participants · 3 Treatment Groups

Primary Treatment: Povorcitinib Dose B · Has Placebo Group · Phase 3

Povorcitinib Dose B
Drug
Experimental Group · 1 Intervention: Povorcitinib · Intervention Types: Drug
Povorcitinib Dose A
Drug
Experimental Group · 1 Intervention: Povorcitinib · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from week 12 through week 54

Who is running the clinical trial?

Incyte CorporationLead Sponsor
325 Previous Clinical Trials
46,460 Total Patients Enrolled
6 Trials studying Hidradenitis Suppurativa
938 Patients Enrolled for Hidradenitis Suppurativa

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
There are other requirements that need to be met for you to participate in the study.
You were diagnosed with moderate to severe HS at least 3 months before the screening visit.
You agree not to get pregnant or father a child during the study.
References

Frequently Asked Questions

Is this research currently in the process of enrolling participants?

"The clinical trial is actively recruiting patients, as evidenced by the information posted on clinicaltrials.gov. This research endeavor was originally advertised on February 22nd 2023 and updated to its current version March 1st 2023." - Anonymous Online Contributor

Unverified Answer

Is Povorcitinib Dose B associated with any potential risks for patients?

"Our team has rated the safety of Povorcitinib Dose B as a 3 due to prior research demonstrating efficacy and numerous rounds of data confirming its security." - Anonymous Online Contributor

Unverified Answer

What is the scope of participants in this medical research?

"This trial necessitates the enrollment of 600 individuals that meet its specified inclusion criteria. Applicants have a choice between Investigative Site US226 in San Diego, Florida and Investigative Site US222 in San Francisco, Illinois." - Anonymous Online Contributor

Unverified Answer

Are there multiple Canadian sites that are facilitating this clinical investigation?

"Apart from the previously mentioned Investigative Sites in San Diego, Florida and Brandon, Indiana; this trial is also recruiting patients at US222 located in San Francisco as well twenty-nine other research centres." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top